Is your knee working as it should?

Knee osteoarthritis is a common form of arthritis. It affects millions of people worldwide. The primary symptoms of osteoarthritis are pain with the use of the knee joint (and later on at rest), as well as stiffness, tenderness, loss of flexibility, and swelling. Answer a few questions to see if you’re eligible for clinical trials that are evaluating investigational treatments with the goal of reducing pain and slowing the progression of knee osteoarthritis.

We’re conducting a program of clinical trials with the aim of developing the next generation of knee osteoarthritis treatments. Current treatments available for knee osteoarthritis only focus on symptomatic relief. In some cases, knee replacement surgery is required. However, these options don’t target the root cause of osteoarthritis, so a different approach to treating the condition is needed. This program of clinical trials includes investigational drugs that will target cartilage regeneration and preservation, as well as pain and inflammation reduction.

Check eligibility

Study details

Participants must:

  • be between 35 and 80 years old
  • have a diagnosis of knee osteoarthritis

Participants must not:

  • Be pregnant or nursing (or planning to become pregnant or nurse during the trial)
  • Have a known autoimmune disease with associated joint inflammation, infection of the joint, Lyme disease involving the knee, systemic cartilage disorder or known systemic connective tissue disease
  • Be unable to undergo magnetic resonance imaging (MRI) scans

If you would like to speak to someone regarding this trial, first check to see if you are initially eligible through the prescreener above. If it seems that you are eligible to take part, you will be contacted by phone so we can ask you additional questions to confirm your eligibility, and you will be able to ask any questions you may have about this clinical trial. If you are not eligible based on your responses to the prescreener, you can always contact us at to discuss further.